Skip to main content

Table 5 Vitamin K agonist resumption

From: Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice

  French guidelines  
  Non-valvular atrial fibrillation Venous thromboembolic disease Mechanical heart valve  
  Should definitively stop taking VKA after ICH Bridging anticoagulation period; VKA resumption to be discussed Bridging anticoagulation period; eligible to resume long-term VKA  
Overall population     Total
   Number 342 101 38 516
   VKA resumption 88 (25.7) 33 (32.7) 11 (28.9) 136 (26.4)
ICH     
   Number 137 31 16 199
   VKA resumption 15 (10.9) 4 (12.9) 4 (25.0) 21 (10.5)
  1. Results are expressed as number (percentage). Results are presented in patients at day 15 after prothombin complex concentrate infusion. ICH, intracranial hemorrhage; VKA, vitamin K antagonist.